[Cell Communication and Signaling] Researchers performed MSC infusion on an animal model of acute-on-chronic alcohol-induced liver injury. MSC therapy ameliorated liver damage, and elevated the proportion of Tregs by secreting cellular retinoic acid binding protein 2 (CRABP2).

[Aminex Therapeutics, Inc.] Aminex Therapeutics, Inc. announced the initiation of & first patient treated in a Phase 1b/2 clinical trial of AMXT 1501 in combination with difluoromethylornithine (DFMO) in patients with breast cancer or metastatic melanoma.

[Kazia Therapeutics Limited] Kazia Therapeutics provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage, Stage IV, metastatic TNBC.

[Nature Cancer] Scientists discovered that targeted inhibition of F-box protein FBXL2 elevates HER2 expression on the plasma membrane of HER2-immunohistochemistry score 0 TNBC cells, thereby sensitizing them to trastuzumab deruxtecan.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified FcγRIIB as the key transporter mediating maternal immunoglobulin G (IgG) transfer across the mammary gland in mammals. Using constitutive and conditional knockout mice, they demonstrated that FcγRIIB deficiency impairs mammary IgG transfer.

[Cell Death & Disease] To dissect the temporal chromatin-based transcriptional response to transforming growth factor β (TGFβ), investigators employed 3D culture models of isogenic human breast epithelial cells, exemplified by non-oncogenic MCF-10A and their HRAS-transformed counterpart.

[EMBO Reports] To investigate the role of enhancer of zeste homolog 2 (EZH2) in HER2+ tumor progression, scientists crossed a genetically engineered mouse model of HER2-driven breast cancer with a conditional Ezh2 knockout strain.

[Translational Oncology] Researchers demonstrated that Ubiquitin-conjugating enzyme E2C (UBE2C) is significantly upregulated in breast cancer and promotes its malignant progression.

[BMC Cancer] Investigators presented an integrative pan-cancer framework linking CD26 expression to immune infiltration, together with in vitro observations in breast cancer cells.

[Histopathology] Scientists summarizes the molecular pathology of phyllodes tumors, the use of these data in developing a model of phyllodes tumor pathogenesis, and how molecular pathology might be applied to aid diagnosis and treatment.

[Cancer Immunology Research] Researchers described the characterization of MiNK-215, an allogeneic human invariant NK T (iNKT) cell therapy in which iNKT cells were engineered to express an fibroblast activation protein (FAP)-targeting CAR and to secrete IL15 to remodel the tumor microenvironment and enhance antitumor activity.

[Cancer Immunology Research] Scientists investigated a universal strategy for boosting transferred tumor-specific T cells for which boosting is provided through a CAR that is paired with a vaccine encoding the CAR target antigen.